To determine the persistence of human papillomavirus (HPV) infection following treatment of HPV-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC).
Methods:
A cross-sectional study was undertaken at The Ottawa Hospital (Ottawa, ON, Canada), a tertiary academic hospital and regional cancer center. Adult patients who were diagnosed with HPV + OPSCC between the years of 2014 and 2016 and treated with curative intent, and who were alive and willing to consent were eligible for inclusion. A saliva assay was used to test for the presence of HPV DNA in a random sample of patients. qPCR was used to amplify DNA from saliva samples.
Results:
Saliva samples were obtained from 69 patients previously treated with HPV + OPSCC. All patients had a minimum of 2 years of follow-up. 5 patients tested positive for HPV: 2 were positive for HPV-16, 2 for HPV-18, and 1 “other” HPV type. No patient in our study cohort had suffered recurrence post-treatment.
Conclusions:
This study is the first to demonstrate the prevalence of persistent oncogenic HPV DNA in saliva following treatment for HPV + OPSCC. This prevalence appears to be low, despite the fact that persistent HPV infection is a precursor for the development of HPV + OPSCC. This finding raises questions about what factors influence the clearance or persistence of HPV DNA in saliva after treatment for HPV + OPSCC, and may add to our understanding about the longitudinal effects of HPV infection in these cancers.
ChaturvediAKEngelsEAAndersonWFGillisonML.Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612-619. doi:10.1200/JCO.2007.14.1713
2.
PulteDBrennerH.Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15(9):994-1001. doi:10.1634/theoncologist.2009-0289
3.
Osazuwa-PetersNSimpsonMCMassaSTAdjei BoakyeEAntisdelJLVarvaresMA.40-Year incidence trends for oropharyngeal squamous cell carcinoma in the United States. Oral Oncol. 2017;74:90-97. doi:10.1016/j.oraloncology.2017.09.015
4.
SaraiyaMUngerERThompsonTD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086. doi:10.1093/jnci/djv086
5.
ViensLJHenleySJWatsonM, et al. Human papillomavirus-associated cancers – United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661-666. doi:10.15585/mmwr.mm6526a1
6.
Karim-KosHEde VriesESoerjomataramILemmensVSieslingSCoeberghJW.Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345-1389. doi:10.1016/j.ejca.2007.12.015
7.
LigierKBelotALaunoyG, et al. Descriptive epidemiology of upper aerodigestive tract cancers in France: incidence over 1980-2005 and projection to 2010. Oral Oncol. 2011;47(4):302-307. doi:10.1016/j.oraloncology.2011.02.013
8.
HakulinenTTryggvadóttirLGislumM, et al. Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):561-577. doi:10.3109/02841860903575307
9.
CrocettiECapocacciaRCasellaC, et al. Population-based incidence and mortality cancer trends (1986–1997) from the network of Italian cancer registries. Eur J Cancer Prev. 2004;13(4):287-295. doi:10.1097/01.cej.0000136719.42948.5a
10.
AngKKHarrisJWheelerR, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi:10.1056/NEJMoa0912217
11.
MirghaniHBelleraCDelayeJ, et al. Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiol. 2019;61:89-94. doi:10.1016/j.canep.2019.05.007
12.
LassenPEriksenJGHamilton-DutoitSTrammTAlsnerJOvergaardJ.Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(12):1992-1998. doi:10.1200/JCO.2008.20.2853
13.
NaghaviAOStromTAbuodehYA, et al. Risk factors for recurrence in human papillomavirus–positive oropharyngeal cancer. Int J Radiat Oncol. 2016;96(2):E372-E373. doi:10.1016/j.ijrobp.2016.06.1568
14.
HongAZhangXJonesD, et al. E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer. Cancer Biol Ther. 2016;17(2):181-187. doi:10.1080/15384047.2015.1108489
15.
O’SullivanBHuangSHSiuLL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543-550. doi:10.1200/JCO.2012.44.0164
16.
MüngerKWernessBADysonNPhelpsWCHarlowEHowleyPM.Complex formation of human papillomavirusE7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989;8(13):4099-4105. doi:10.1002/j.1460-2075.1989.tb08594.x
17.
DysonNHowleyPMMüngerKHarlowE.The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934-937. doi:10.1126/science.2537532
18.
SmithEMSwarnavelSRitchieJMWangDHaugenTHTurekLP.Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J. 2007;26(9):836-840. doi:10.1097/INF.0b013e318124a4ae
19.
HanssonBGRosenquistKAntonssonA, et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol. 2005;125(12):1337-1344. doi:10.1016/s1041-892x(07)70241-x
GiovannelliLCampisiGLamaA, et al. Human papillomavirus DNA in oral mucosal lesions. J Infect Dis. 2002;185(6):833-836. doi:10.1086/339193
22.
WassermanJKRourkeRPurginaB, et al. HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours. J Otolaryngol Head Neck Surg. 2017;46(1):3. doi:10.1186/s40463-016-0179-6
23.
HoffmanSRLeTLockhartA, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. Int J Cancer. 2017;141(1):8-23. doi:10.1002/ijc.30623
24.
ZhangHZhangTYouZZhangY.Positive surgical margin, HPV persistence, and expression of both TPX2 and PD-L1 are associated with persistence/recurrence of cervical intraepithelial neoplasia after cervical conization. PLoS One. 2015;10:e0142868. doi:10.1371/journal.pone.0142868
25.
KreimerARPierce CampbellCMLinHY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382(9895):877-887. doi:10.1016/S0140-6736(13)60809-0
26.
HannaGJLauCJMahmoodU, et al. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019;95:120-126. doi:10.1016/j.oraloncology.2019.06.019
